



Portland Investment Counsel[®]
Buy. Hold. And Prosper.[®]

PORTLAND 15 OF 15 ALTERNATIVE FUND

NEWS UPDATE

Clarity Receives FDA Fast Track Designation For ⁶⁴Cu-SAR-bisPSMA

Clarity Pharmaceuticals (Clarity) has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its imaging agent ⁶⁴Cu-SAR-bisPSMA* for the detection of PSMA-positive prostate cancer lesions in patients with suspected metastasis.

The FDA's Fast Track Designation aims to speed up the development and review process for novel drugs addressing serious conditions with unmet medical needs. In particular, the designation paves the way for a potentially faster review process once Clarity submits its product approval application. Dr. Alan Taylor, Clarity's Executive Chairperson, highlighted the significance of this milestone, particularly as the company is actively recruiting for its registrational Phase III trial, CLARIFY, and preparing for an FDA meeting regarding a second Phase III trial.

For further details, please refer to the [press release](#).

Clarity is an investment currently held in the [Portland 15 of 15 Alternative Fund](#) (the Fund); please visit the Fund's website for further information.

The Fund's objective is to provide positive long-term total returns by investing primarily in a portfolio of global equities and debt-like securities. In selecting its investment, the Fund considers 15 principles/attributes which the Manager believes will result in successful wealth creation.

**⁶⁴Cu-SAR-bisPSMA is a Positron Emission Tomography (PET) imaging agent used for detecting prostate-specific membrane antigen (PSMA)-positive prostate cancer*

⁶⁴Cu - Copper-64, a radioactive isotope of copper used in medical imaging.

SAR - "Sarcophagine," a chelator that binds the copper isotope to the targeting molecule.

bisPSMA - molecule that targets PSMA (Prostate-Specific Membrane Antigen), which is commonly overexpressed in prostate cancer cells.



Portland Investment Counsel[®]
Buy. Hold. And Prosper.[®]

PORTLAND 15 OF 15 ALTERNATIVE FUND

NEWS UPDATE

 [Portland Investment Counsel Inc.](#)

 [portlandinvestmentcounsel](#)

 [Portland Investment Counsel Inc.](#)

 [@PortlandCounsel](#)

RISK TOLERANCE

Risk tolerance measures the degree of uncertainty that an investor can handle regarding fluctuations in the value of their portfolio. The amount of risk associated with any particular investment depends largely on your own personal circumstances including your time horizon, liquidity needs, portfolio size, income, investment knowledge and attitude toward price fluctuations. Investors should consult their financial advisor before making a decision as to whether this Fund is a suitable investment for them.

Commissions, trailing commissions, management fees and expenses all may be associated with mutual fund investments. Please read the prospectus before investing. Mutual funds are not guaranteed, their values change frequently and past performance may not be repeated.

Consent is required for any reproduction, in whole or in part, of this piece and/or of its images and concepts. Portland Investment Counsel is a registered trademark of Portland Holdings Inc. The Unicorn Design is a trademark of Portland Holdings Inc. Used under license by Portland Investment Counsel Inc. Buy. Hold. And Prosper. is a registered trademark of AIC Global Holdings Inc. used under license by Portland Investment Counsel Inc.

Portland Investment Counsel Inc., 1375 Kerns Road, Suite 100, Burlington, Ontario L7P 4V7 Tel: 1-888-710-4242 • [www.portlandic.com](#) • [info@portlandic.com](#)